Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard...

Full description

Bibliographic Details
Main Authors: Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Format: Article
Language:English
Published: Nature Publishing Group 2023-08-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00886-8

Internet

https://doi.org/10.1038/s41408-023-00886-8

Similar Items